MTAP Antibody (1113601) [Alexa Fluor™ Plus 555]

• Reactivity: Hu
• Clone: 1113601
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor Plus 555

MTAP Antibody (1113601) [Alexa Fluor™ Plus 555] Summary

• Specificity: Detects recombinant human MTAP protein in Direct ELISA
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for MTAP Antibody (1113601) [Alexa Fluor™ Plus 555]

• 5'-methylthioadenosine phosphorylase
• BDMF
• C86fus
• DMSFH
• DMSMFH
• EC 2.4.2.28
• HEL-249
• LGMBF
• methylthioadenosine phosphorylase
• MSAPMeSAdo phosphorylase
• MTA phosphorylase
• MTAP
• MTAPase
• S-methyl-5'-thioadenosine phosphorylase

Background

Methyl-thioadenosine phosphorylase/MTAP is part of the PNP/MTAP phosphorylase family and catalyzes the reversible phosphorylation of S-methyl-5'-thioadenosine (MTA), a major byproduct of polyamine synthesis essential for cell growth and proliferation. MTAP also produces most of the free adenine generated in human cells through a salvage pathway and thus couples the purine salvage pathway with polyamine biosynthesis. MTAP forms an active trimer where each identical 32 kDa monomer contains a separate active site (1). Each active site contains three distinct regions required for base-, methylthioribose-, and sulfate/phosphate-binding (1). MTAP is cytosolic and abundantly expressed in normal cells and tissues (2). In contrast, deficient MTAP expression is observed in many types of tumors including lung, bladder, pancreatic, and endometrial cancer (3) due to hyper-methylation gene suppression (4) or gene deletion (3, 5, 6). MTA accumulation leads to an immunosuppressive tumor microenvironment and apoptotic resistance (7-9) and MTAP directly regulates the level of MTA present. MTAP has been reported as a tumor suppressor (6,10) that may also act in a manner that is independent of enzymatic activity (11) through signaling pathways such as the insulin-like growth factor-1 receptor pathway (12). Potential therapeutic strategies to exploit MTAP deficiency in tumors (13,14) or inhibit MTAP in tumors that express MTAP, such as prostate cancer, are under investigation (15).

1. Appleby, T.C. et al. (1999) Structure 7:629.
2. Garbers, D.L. (1978) Biochim. Biophys. Acta. 523:82.
3. Li, Y. et al. (2019) J. Cancer 10:927.
4. Hellerbrand, C. et al. (2006) Carcinogenesis 27:64.
5. Cairns, P. et al. (1995) Nat. Genet. 11:210.
6. Christopher, S.A. (2002) Cancer Res. 62:6639.
7. Kirovski, G. et al. (2011) Am. J. Pathol. 178:1145.
8. Czech, B. et al. (2013) PLoS One 8:e80703.
9. Henrich, F.C. et al. (2016) Oncoimmunology 5:e1184802.
10. Kadariya, Y. et al. (2009) Cancer Res. 69:5961.
11. Tang, B. et al. (2014) G3 (Bethesda) 5:35.
12. Xu, J. et al. (2019) Signal Transduct. Target Ther. 4:2.
13. Bertino, J.R. et al. (2011) Cancer Biol. Ther. 11:627.
14. Tang, B. et al. (2018) Cancer Res. 78:4386.
15. Bistulfi, G. et al. (2016) Oncotarget 7:14380.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.